NCT01536405View on ClinicalTrials.gov

Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,412

Participants

Timeline

Start Date

June 5, 2012

Primary Completion Date

July 2, 2013

Study Completion Date

January 27, 2014

Conditions
MeaslesMumpsRubellaVaricella
Interventions
BIOLOGICAL

MMRV (AMP)

Measles, mumps, rubella, and VZV vaccine made with an alternative manufacturing process. Participants will receive two 0.5 mL subcutaneous injections.

BIOLOGICAL

MMRV (2006 process)

Measles, mumps, rubella, and VZV vaccine made with the 2006 manufacturing process. Participants will receive two 0.5 mL subcutaneous injections.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01536405 - Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027) | Biotech Hunter | Biotech Hunter